LabTube is no longer active

LabTube is no longer accepting new video uploads, and will shortly be rolled down.

On our parent publication, Technology Networks, you’ll be able to find videos covering a range of topics across the life sciences, applied markets, analytical sciences, drug discovery and more. Click here to learn more.

LP-284 Targets Non-Hodgkin's Lymphoma and DNA Damage Repair Deficiency



June 12, 2023

  • Share
  • Oncotarget published this research paper on June 12, 2023 in Volume 14, entitled, “LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair" by researchers from Lantern Pharma Inc., Plano, TX; Department of Medicine, Duke University, Durham, NC; Data Driven Bioscience, Durham, NC. DOI - Correspondence to - Jianli Zhou - Abstract Despite advances in therapies treating non-Hodgkin’s lymphoma (NHL), 20~40% of patients experience relapsed or refractory disease. While solid tumors with homologous recombination deficiencies have been successfully targeted with synthetic lethal agents such as poly-ADP ribose polymerase (PARP) inhibitors, such synthetic lethality strategy has not yet been approved to treat patients with NHL. Here we investigated the mechanism of action (MoA) and therapeutic potential of a new-generation acylfulvene compound, LP-284, in both in vitro and in vivo NHL models. One of LP-284’s MoA includes inducing the repair of double-strand DNA break (DSB). We found that LP-284 exerts nanomolar potency in a panel of hematological cancer cell lines including fifteen NHL cell lines. In vivo, LP-284 treatment prolongs the survival of mantle cell lymphoma (MCL) cell line JeKo-1 derived xenograft mice by two-fold and shows increased efficacy over bortezomib and ibrutinib. In addition, LP-284 is capable of inhibiting tumor growth of JeKo-1 xenografts that are refractory to bortezomib or ibrutinib. We further showed that LP-284 is particularly lethal in cells with deficient DNA damage response and repair, a targetable vulnerability in NHL. Sign up for free Altmetric alerts about this article - Subscribe for free publication alerts from Oncotarget - Keywords - non-Hodgkin's lymphoma, DNA damage, homologous recombination repair, transcription-coupled nucleotide excision repair, ATM About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit and connect with us: SoundCloud - Facebook - Twitter - Instagram - YouTube - LinkedIn - Pinterest - Reddit - Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

    Cancer ResearchCell ScienceDrug DiscoveryMolecular Biology

    Keep up to date with all your favourite videos and channels.

    Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.